Marques Sérgio M, Šupolíková Lucie, Molčanová Lenka, Šmejkal Karel, Bednar David, Slaninová Iva
Loschmidt Laboratories, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment RECETOX, Faculty of Science, Masaryk University, Kamenice 5/C13, 625-00 Brno, Czech Republic.
International Clinical Research Center, St. Anne's University Hospital Brno, Pekarska 53, 656-91 Brno, Czech Republic.
Biomedicines. 2021 Mar 30;9(4):357. doi: 10.3390/biomedicines9040357.
Multidrug resistance (MDR) is a common problem when fighting cancer with chemotherapy. P-glycoprotein (P-gp, or MDR1) is an active pump responsible for the efflux of xenobiotics out of the cell, including anti-cancer drugs. It is a validated target against MDR. No crystal structure of the human P-gp is available to date, and only recently several cryo-EM structures have been solved. In this paper, we present a comprehensive computational approach that includes constructing the full-length three-dimensional structure of the human P-gp and its refinement using molecular dynamics. We assessed its flexibility and conformational diversity, compiling a dynamical ensemble that was used to dock a set of lignan compounds, previously reported as active P-gp inhibitors, and disclose their binding modes. Based on the statistical analysis of the docking results, we selected a system for performing the structure-based virtual screening of new potential P-gp inhibitors. We tested the method on a library of 87 natural flavonoids described in the literature, and 10 of those were experimentally assayed. The results reproduced the theoretical predictions only partially due to various possible factors. However, at least two of the predicted natural flavonoids were demonstrated to be effective P-gp inhibitors. They were able to increase the accumulation of doxorubicin inside the human promyelocytic leukemia HL60/MDR cells overexpressing P-gp and potentiate the antiproliferative activity of this anti-cancer drug.
多药耐药性(MDR)是化疗抗癌时常见的问题。P-糖蛋白(P-gp,或MDR1)是一种主动转运泵,负责将包括抗癌药物在内的外源性物质排出细胞。它是对抗MDR的一个已验证靶点。迄今为止,尚无人类P-gp的晶体结构,直到最近才解析出几个冷冻电镜结构。在本文中,我们提出了一种全面的计算方法,包括构建人类P-gp的全长三维结构并使用分子动力学对其进行优化。我们评估了其灵活性和构象多样性,编制了一个动力学系综,用于对接一组先前报道为活性P-gp抑制剂的木脂素化合物,并揭示它们的结合模式。基于对接结果的统计分析,我们选择了一个系统来对新的潜在P-gp抑制剂进行基于结构的虚拟筛选。我们在文献中描述的87种天然黄酮类化合物库上测试了该方法,并对其中10种进行了实验测定。由于各种可能的因素,结果仅部分重现了理论预测。然而,至少有两种预测的天然黄酮类化合物被证明是有效的P-gp抑制剂。它们能够增加阿霉素在过表达P-gp的人早幼粒细胞白血病HL60/MDR细胞内的积累,并增强这种抗癌药物的抗增殖活性。